莫沙必利联合黛力新治疗慢性胃炎的临床效果研究(1)
摘要：目的： 探究莫沙必利联合黛力新治疗慢性胃炎的临床效果。方法： 选取我院2014年8月～2015年6月收治的96例慢性胃炎患者作为研究对象，采取随机数字表法将所有患者分为实验组(48例)与对照组(48例)，对照组患者予以莫沙必利治疗，实验组在对照组患者治疗基础上联合黛力新进行治疗，对比两组患者临床治疗效果及不良反应情况，采取焦虑自评量表(SAS)及抑郁自评量表(SDS)评定患者心理状况。结果 ： 经治疗后实验组患者总有效率为95.83%，对照组总有效率为83.33%，实验组总有效率明显高于对照组，p<0.05，差异具有统计学意义；治疗后两组患者SAS、SDS评分对比，实验组明显优于对照组，p<0.01，差异具有统计学意义；两组患者治疗后均严重不良反应出现，对照组出现1例不安，1例躁动，实验组出现1例调节障碍，两组总不良反应率对比无差异(p>0.05)。结论： 慢性胃炎患者采取莫沙必利联合黛力新治疗临床效果显著，可明显提升总有效率，改善患者临床症状及心理状态，促进患者康复，且不良反应少，安全性高，具有较高的临床应用价值。
, http://www.100md.com 关键词：慢性胃炎；黛力新；莫沙必利；总有效率；心理状况
Abstract：Purpose Moser will benefit joint d force new clinical effect for the treatment of chronic gastritis. Methods Selected from August 2014 to June 2015 treated 96 cases of chronic gastritis patients as the research object， take a random number table method all patients were divided into experimental group (48 cases) and control group (48 cases) and control group patients give moser will the treatment， the experimental group patients in the control group on the basis of joint force new treatment， compared two groups of patient's clinical curative effect and adverse reaction， self-evaluation of anxiety scale (SAS) and self rating scale for depression (SDS) to evaluate the patients psychological status.Results Experimental group patients after treatment the total effective rate was 95.83%， control group total effective rate was 83.33%， the experimental group total effective rate is significantly higher than the control group， p < 0.05， the difference is statistically significant； In the two groups after treatment in patients with SAS， SDS score comparison， the experimental group was better than control group， p < 0.01， the difference is statistically significant； All serious adverse reactions after treatment in both groups， control group in 1 case， 1 case of agitation， the experimental group in 1 case of adjustment disorder， the total rate of adverse reactions to contrast differences between the two groups (p > 0.05). Conclusion Take moser will benefit patients with chronic gastritis with Diane force new therapy clinical effect is remarkable， can obviously improve total effective rate， improve patient's clinical symptoms and psychological state， promote patients recovery， and less adverse reaction， high safety， has high clinical value.
, http://www.100md.com
Keywords：Chronic gastritis； Her new force； Moser will benefit； Total effective rate； Psychological status
慢性胃炎是临床消化内科较为常见的多发病，该病病程较长，发病原因较多，包括食用刺激性食物、幽门螺杆菌感染、长期精神紧张以及遗传因素等[1]。其主要临床表现为腹部胀痛不适、恶心、呕吐、反酸、睡眠障碍等。有研究显示[2]，我国接受内镜检查患者80%～90%，50岁以上患者发病率高达50%。随着人们生活节奏的加快及工作压力等因素影响，慢性胃炎发病率越来越高，严重影响患者身心健康，引起临床高度重视[3]。为了研究治疗慢性胃炎的最佳方法，我院选取96例慢性胃炎患者进行莫沙必利联合黛力新治疗效果研究，取得一定成果，现将研究结果进行如下详细汇报。, http://www.100md.com(郑毅平)
, http://www.100md.com 关键词：慢性胃炎；黛力新；莫沙必利；总有效率；心理状况
Abstract：Purpose Moser will benefit joint d force new clinical effect for the treatment of chronic gastritis. Methods Selected from August 2014 to June 2015 treated 96 cases of chronic gastritis patients as the research object， take a random number table method all patients were divided into experimental group (48 cases) and control group (48 cases) and control group patients give moser will the treatment， the experimental group patients in the control group on the basis of joint force new treatment， compared two groups of patient's clinical curative effect and adverse reaction， self-evaluation of anxiety scale (SAS) and self rating scale for depression (SDS) to evaluate the patients psychological status.Results Experimental group patients after treatment the total effective rate was 95.83%， control group total effective rate was 83.33%， the experimental group total effective rate is significantly higher than the control group， p < 0.05， the difference is statistically significant； In the two groups after treatment in patients with SAS， SDS score comparison， the experimental group was better than control group， p < 0.01， the difference is statistically significant； All serious adverse reactions after treatment in both groups， control group in 1 case， 1 case of agitation， the experimental group in 1 case of adjustment disorder， the total rate of adverse reactions to contrast differences between the two groups (p > 0.05). Conclusion Take moser will benefit patients with chronic gastritis with Diane force new therapy clinical effect is remarkable， can obviously improve total effective rate， improve patient's clinical symptoms and psychological state， promote patients recovery， and less adverse reaction， high safety， has high clinical value.
, http://www.100md.com
Keywords：Chronic gastritis； Her new force； Moser will benefit； Total effective rate； Psychological status
慢性胃炎是临床消化内科较为常见的多发病，该病病程较长，发病原因较多，包括食用刺激性食物、幽门螺杆菌感染、长期精神紧张以及遗传因素等[1]。其主要临床表现为腹部胀痛不适、恶心、呕吐、反酸、睡眠障碍等。有研究显示[2]，我国接受内镜检查患者80%～90%，50岁以上患者发病率高达50%。随着人们生活节奏的加快及工作压力等因素影响，慢性胃炎发病率越来越高，严重影响患者身心健康，引起临床高度重视[3]。为了研究治疗慢性胃炎的最佳方法，我院选取96例慢性胃炎患者进行莫沙必利联合黛力新治疗效果研究，取得一定成果，现将研究结果进行如下详细汇报。, http://www.100md.com(郑毅平)